[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008035463A1 - Procédé de commutation de classe d'anticorps - Google Patents

Procédé de commutation de classe d'anticorps Download PDF

Info

Publication number
WO2008035463A1
WO2008035463A1 PCT/JP2007/001029 JP2007001029W WO2008035463A1 WO 2008035463 A1 WO2008035463 A1 WO 2008035463A1 JP 2007001029 W JP2007001029 W JP 2007001029W WO 2008035463 A1 WO2008035463 A1 WO 2008035463A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
gene
producing
cell
cells
Prior art date
Application number
PCT/JP2007/001029
Other languages
English (en)
Japanese (ja)
Inventor
Hidetaka Seo
Original Assignee
Chiome Bioscience Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc. filed Critical Chiome Bioscience Inc.
Publication of WO2008035463A1 publication Critical patent/WO2008035463A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Definitions

  • the present invention relates to a method for converting a class of an antibody.
  • Antibodies recognize specific antigens, cause various in vivo phenomena, and play an important role as in-vivo defense players.
  • antibody-dependent cell — mediated cytotoxicity (ADCC) activity and complement-dependent cell I (CDC) activity are effective in removing cancer cells. It is used as an anticancer agent. Focusing on the action of such antibodies, many antibody preparations have been put to practical use, and many preparations have good therapeutic effects. In addition to its use as a pharmaceutical formulation, it is widely used as, for example, various diagnostic tests or effective tools for research and development. Therefore, a technique for easily providing a large amount of various antibodies according to each application is required.
  • Non-Patent Document 2 As a technique for easily and easily producing a large amount of an antibody having high specificity for an arbitrary antigen, a method called AD Lib system is attracting attention (Patent Document 1, Non-Patent Document 2). See). According to this method, an antibody having the desired specificity and affinity can be provided by a simple method.
  • the antibody produced by this method is mainly IgM, but other classes (IgG, IgA, IgD, other than IgM) can be used for various applications of the antibody described above. It will also be necessary to prepare antibodies of IgE).
  • Patent Document 2 As a method for converting the class of an antibody, a method of expressing an IgA class with high efficiency by stimulating B cells with a specific composition (Patent Document 2), using a transgenic non-human animal Various methods have been reported, such as a method for producing a desired isotype (Patent Document 3). Few things have been put to practical use. Since B cells are essentially floating cells that produce antibodies, they have advantages over other animal cell expression systems in terms of high-concentration antibody production, high-density culture, etc., and B cells produce the desired class of antibodies. It will be possible to improve the efficiency of antibody production. However, no effective method has been developed to transduce antibody heavy chain constant region genes into monoclonal antibody-producing B cells that have already been screened to convert the produced monoclonal antibodies to other classes.
  • Non-Patent Document 1 Seo et al., Nature Biotec h. 23: 731-735, 2005
  • Patent Document 1 International Publication Gazette WO 2004/01 1 644
  • Patent Document 2 International Publication WO 96/27390
  • Patent Document 3 International Publication WO 99/03991
  • the present inventors have conducted intensive research on a method for easily converting antibody classes, and as a result, the antibody heavy chain variable region genes produced from antibody-producing B cells and By simply transducing a chimeric heavy chain gene with a heavy chain constant region gene of a desired class mainly into the antibody-producing B cell, an antibody retaining the desired class of the constant region is converted into the antibody-producing B cell. It was revealed that it can be produced from Although it was unclear whether the modified chimeric antibody heavy chain and the already existing antibody light chain would be assembled in the cell by such a method alone, the results of the analysis unexpectedly retain effective functions. The production of chimera IgG was confirmed.
  • the present invention relates to the following (1) to (9).
  • a first aspect of the present invention is a method for improving or preparing an antibody-producing B cell that produces an antibody of a class different from the class of a monoclonal antibody originally produced, comprising the following (a) and ( A method comprising the step of b).
  • step (b) a step of inserting the chimeric gene prepared in step (a) into an expression vector so as to allow expression and transducing the antibody-producing B cell ”.
  • a second aspect of the present invention is “the method according to (1) above, wherein the class of antibody originally produced from the monoclonal antibody-producing B cell is IgM”.
  • a third aspect of the present invention is “the method according to (1) or (2) above, wherein the other class is IgG”.
  • a fourth aspect of the present invention is “the method according to any one of (1) to (3) above, wherein the antibody-producing B cells are DT40 cells”.
  • the fifth aspect of the present invention is the above (1) to (4), wherein the antibody-producing B cell has lost the function of all antibody heavy chain genes present in the cell.
  • a sixth aspect of the present invention is “the method according to any one of (1) to (5) above, wherein the constant region gene is derived from a mouse”.
  • a seventh aspect of the present invention is “the method according to any one of (1) to (5) above, wherein the constant region gene is derived from human”.
  • the eighth aspect of the present invention is “the method according to any one of (1) to (5) above, wherein the constant region gene is derived from a rabbit.”
  • a ninth aspect of the present invention is as described in any one of (1) to (8) above. “Class-changed antibodies obtained from cells prepared by the method”. The invention's effect
  • IgM antibody producing B cells can be readily converted to B cells producing antibodies with the desired class of properties.
  • Fig. 1 shows the results of confirming the presence or absence of production of a chimeric antibody of anti-FITC antibody produced by DT40 cells and mouse IgG2a.
  • FIG. 2 shows the results of E L ISA for a purified chimeric antibody using an HRP-labeled anti-mouse IgG secondary antibody.
  • FIG. 3 shows the results of Western blotting for a purified chimeric antibody using an HRP-labeled anti-mouse IgG secondary antibody.
  • Fig. 4 shows the presence or absence of production of a chimeric antibody between anti-FITC antibody and mouse Ig G 2a produced by DT 40 cells into which the chimeric antibody gene has been introduced using a single retrovirus vector. Results are shown.
  • FIG. 5 shows the results of confirming the presence or absence of the production of a chimeric antibody of anti-EG FR antibody and mouse Ig G 2a.
  • FIG. 6 shows the results of confirming the presence or absence of production of a chimeric antibody of anti-EG FR antibody and human IgG1.
  • Figure 7 shows the F ACS analysis by staining A 43 1 cells and HEK 293 T cells with avian anti-EG FR antibody, anti-EG FR mouse chimeric antibody, and anti-EG FR human one-trichimeric antibody. The results are shown.
  • the cells used in the present invention can be any B cells that produce antibodies, and the type of animal from which they are derived may be any animal.
  • cells that are established or not established can be used, but preferably, established cells are used, particularly preferably derived from chickens. It is DT 40 cell which is a cell culture cell line of B cell.
  • antibody-producing cells also include derivative strains and sublines in which some modification to the chromosome (for example, recombination, insertion, deletion, etc. of specific genes) has been made.
  • it may be a cell that has been modified to reduce or lose the function of the antibody heavy chain gene that was originally retained.
  • a method of reducing or losing the function of an antibody heavy chain gene can be easily carried out based on the common general technical knowledge.
  • a method of introducing a mutation into an antibody heavy chain gene originally present in an antibody-producing cell Methods known to those skilled in the art can be used, such as a method of destroying the entire target gene, a method using RNA interference (RNA i), a method of introducing antisense to the target gene into cells.
  • RNA interference RNA interference
  • a method for introducing a mutation into a target gene a method for destroying the entire target gene, or a method using RNA interference (RNA i), more preferably a method for destroying the entire target gene or RNA It is a method using interference (RNA i), and most preferably a method of destroying the entire target gene.
  • RNA interference RNA interference
  • the culture conditions of the cells used in the present invention are carried out by methods well known in the art.
  • Medium and culture conditions suitable for the antibody-producing B cells to be selected (culture temperature, CO 2 concentration) Needless to say, it is done below.
  • the antibody-producing cells selected are DT 40 cells, for example, the medium is IMDM (Invitrogen), and the culture temperature is 39.5 ° C, 5% CO. 2 Perform under concentration conditions. Culturing is carried out while keeping the cell concentration constant, and the class of antibodies produced from the target cells is checked at appropriate intervals (for example, every day or every week).
  • the heavy chain gene of an antibody originally produced from a target antibody-producing B cell can be prepared based on common general technical knowledge in the technical field.
  • the target antibody heavy chain gene region can be amplified from the target antibody-producing B cells using RT_PCR and cloned into an appropriate vector or the like.
  • the primer used for R T_PC R is The sequence information of the antibody heavy chain gene can be obtained from a known database related to the gene possessed by the antibody-producing cell, and designed easily based on this information.
  • a gene encoding the constant region of another class In addition, in order to replace the constant region of the heavy chain gene of the originally produced antibody with the constant region of another class, it is necessary to prepare a gene encoding the constant region of another class.
  • This gene can be obtained from a library such as a cell from which the constant region of the other class is derived, or based on known gene sequence information, the gene of interest can be obtained from an appropriate cDNA library. It can be amplified by PCR.
  • variable region gene and other classes of constant region genes must be operably linked.
  • “being able to act” means that when a variable region gene and a constant region gene of another class are linked, the constant region gene can express a desired polypeptide.
  • the gene reading frame (frame) is linked with the variable region gene reading frame.
  • the variable region gene and the other region of the constant region gene may be directly linked, or an amino acid sequence that serves as a spacer may be inserted. Even when a spacer is inserted, it goes without saying that the reading frame (frame) must be adjusted so that the constant region gene can express the desired polypeptide.
  • other classes of constant region genes encode additional genes, for example, peptides that serve as tags for easy purification (for example, epitope tags such as His tags, peptide tags, GST, etc.) Genes to be operably linked may be linked.
  • the chimeric gene prepared as described above is a polypeptide that codes for the variable region gene of the antibody heavy chain gene derived from antibody-producing B cells, and a gene that codes for the other region of the constant region gene.
  • a chimeric antibody heavy chain polypeptide linked with peptides is coded.
  • the expression vector preferably has a component such as a plug motor or an enhancer that allows the target protein to be expressed in the antibody-producing B cells used.
  • Introducing the prepared expression vector into antibody-producing B cells uses known methods such as the DEAE dextran method, electrorevolution method, calcium phosphate method, cationic lipid method, infection using retroviral vectors, etc. It can be done easily. In particular, a method using a retroviral vector that can reduce the total number of steps is most desirable.
  • the plasmids p L PCX_F I TC_m I g G 2a and p L PCX-EG FR-h I gG 1 prepared in the examples of the present invention represent the sequence of the variable region of the avian antibody in the gene common to the region. By converting by an engineering method, it can be easily used to create chimeric genes of different types of avian antibodies. This makes it possible to shorten the total process.
  • Cell culture of DT 40 cells was basically performed by the following method.
  • the incubator was a C02 thermostatic chamber and cultured at 39.5 ° C in the presence of 5% C02.
  • the medium is IMMD medium (Invitrogen), 10% FBS, 1% chicken serum, penicillin 100 units / mI, streptomycin 100 g I, 2_mercaptoethanol 55 M Used in addition.
  • Trichostatin A (Wako Pure Chemical Industries) is dissolved in DMSO 2 mg / m I as stock, and diluted appropriately in the medium so that the final concentrations are 1.25 ng / mL and m2.5 ng / mL. Used.
  • Antibody producing cells were obtained by the AD Lib system using FITC-conjugated BS A as an antigen. Specifically, the following experimental process was taken. 2-1. Preparation of FITC-conjugated BSA magnetic beads:
  • buffer D 0.2 MT ris-HCI pH 8.5, 0.1% BSA
  • 200 ⁇ I were added, and the mixture was allowed to react at 37 ° C for 4 hours with rotation and stirring, followed by blocking. It was. After washing twice with 500 I buffer C, the suspension was suspended in 200 I buffer containing 0.02 ⁇ 1 ⁇ 2 sodium azide.
  • ELISA was performed as follows. Six days after step 2_2 above, dispense 1 00 L each into 9 6-hole immunoplate U— 9 6 M axisorp (Nunc) at 1 g of F 1 ⁇ 0 conjugate ⁇ 38 2.5 g / m L I left it. In order to examine the specificity of the antibody, BSA not labeled with FITC was also immobilized on the plate as a control. Discard the contents the next day and block the buffer (PBS containing 0.5% skim milk) 200 UL was added and incubated for 2 hours at room temperature. ELISA wash buffer
  • RNeasyPluin Minik QIAGEN
  • QIA shr d der QIA AG
  • RT_PCR was Invitrogen's One Step RT-PCR.
  • I Tal RNA 1 I was in a saddle type, and two types of primers_ (VH_F1: self-sequence number 1, VH—R: SEQ ID NO: 2) were used.
  • the reaction conditions are as follows. 5 After 5 min at 30 ° C, treatment for 2 min at 94 ° C, 9 4 ° C for 15 sec, 60 ° C for 30 sec, 68 min for 1 min 28 cycles It was. The mixture was then incubated for 5 minutes at 68 ° C.
  • the heavy chain fragment obtained by RT_PCR was obtained using the DH5 strain.
  • TA cloning to pCR 2.1—TOPO vector (Invitrogen) gave pANTI_FIT C_HC.
  • the sequence was confirmed using an ABI prism 377 sequencer.
  • Mouse IgG2a cloning uses Mouse Spleen BD Ma ratho n-Re adyc DNA (Clontech) as a saddle, and two primers (mIgG2aF-1: SEQ ID NO: 3, mlg G 2 a R-1: ⁇ ⁇ ⁇ 1 J number 4) was used for PCR with Pyrobestpolylase (SSia).
  • the reaction conditions are as follows. After 98 ° C for 2 minutes, 98 ° C for 30 seconds, 55 ° C for 30 seconds, 72 ° C for 2 minutes were reacted for 30 minutes at 72 ° C for 5 minutes.
  • the mouse I g G 2 a F c region fragment obtained here was added with “A” by adding E x T aq (Takara Shuzo) and reacting at 72 ° C for 15 minutes, and then using the DH 5 strain.
  • PCR2. 1 TOPO vector (Invitrogen) was TA-cloned to obtain pM IgG2a. The sequence was confirmed using AB I prism 377 sequencer.
  • pAN TI _F I TC—HC is of a saddle type
  • the primer is VH—F 1 and Gd I gM-CH 1 + m I g G 2 a -R: a combination of SEQ ID NO: 5
  • pM I g G 2 a is a saddle type
  • Primer was performed with Gd I gM-CH 1 + m I g G 2 a-F: SEQ ID NO: 6 and m I g G 2 a R-1: SEQ ID NO: 4 .
  • the conditions were 98 ° C for 2 minutes, 98 ° C for 30 seconds, 55 ° C for 30 seconds, and 72 ° C for 1 minute after 15 cycles, followed by reaction at 72 ° C for 5 minutes.
  • the band amplified in (i) and (ii) was purified by Qiaquick Gel Extraction Minikit (QI AGEN), and the mixture of fragments 1 L each was used as a saddle type, and (i), (ii PCR was carried out under the same reaction conditions as in). Note that the primer is V H_ F 1 and , Ml gG2 a R_1 was used under the following conditions.
  • the obtained chimera gene fragment is added with “A” by adding E x T aq (Takara Shuzo) and reacting at 72 ° C for 15 min, and using DH 5 strain, p CR 2.1 vector Cloned and obtained pANTI-FIT C-mG 2a.
  • the sequence was confirmed by ABI AB I pri sm377 sequencer.
  • P EG FP—C 1 (Clontech) was used as the expression vector.
  • p EG F PC 1 is digested with the restriction enzymes N he I and B am H I, and the end of the vector is smoothed with Klenow Fragment (Takara Shuzo) and then removed with BAP (Takara Shuzo). Phosphorylated.
  • the chimeric gene to be inserted was obtained by blunting the EcoR I fragment derived from pAN T I — F I TC — mG2a.
  • Both the vector 1 and the insert were purified by Q i aq u i c k G e l e x t r a c t i o n k i t (Q i a g e n company), and then subjected to ligation using L i gat i o n k i t v e r 2 (Takara Shuzo). Transformation was performed on DH 5 strains.
  • the expression construct of the chimeric antibody obtained in 4_1 above was introduced into an anti-FITC antibody production strain. Gene transfer was performed using electroporation. About 20 g equivalent is digested with the restriction enzyme M I u I to make a single strand, and after purification, PBS, 500! Dissolved in _. About 107 anti-FITC antibody-producing strains were electroporated under conditions of about 550 V and 25 F, then left on ice for 10 minutes, transferred to 20 mL of medium, and cultured at 37 ° C for 1 hour. .
  • the culture solution is centrifuged (190 xg, 10 min), and the cells are collected in a pellet and then suspended in 80 mL of medium containing 2 mg / mL G41 8 (Invitrogen). After dispensing at 200 L / well, the cells were cultured at 39.5 ° C.
  • the chimeric antibody was purified from the No. 3 clone prepared in 5 above, and the characteristics were further examined in detail.
  • Centrifugation was performed at 500 X g, and 10 ml of chicken serum (In Vitrogen) from which the precipitate was removed was added to 10 ml of saturated ammonium sulfate solution, and ammonium sulfate precipitation was performed at 4 ° C. The next day, the mixture was centrifuged at 9100 xg for 15 minutes, and the supernatant was collected. The mixture was centrifuged again at 91 00 X g for 15 minutes, and the supernatant was collected.
  • the supernatant was filtered through a 0.45 m filter (Zartorius), transferred to a dialysis tube (Spectrapore, MWCO: 3 500, 9.3 mL / cm), and 3 times against 1 L of PBS. (Of which 2 times Dialysis was performed at 4 ° C for 4 hours once.
  • the sample was taken out from the dialysis tube the next day and concentrated to 1 OmL at 2330 xg with Centrip Ius YM3 (Mii II ipore). After concentration, the solution was sterilized with a 0.22 m filter (Sartorius), dispensed in appropriate amounts, and stored frozen at 30 ° C.
  • Cells diluted with semi-serum-free medium to 2 X 106 L were prepared in 50 mL (total 200 mL) for four 14 cm dishes (Nunc Corporation). This was cultured in a CO 2 incubator at 39.5 ° C and 5% CO 2 for 5 days.
  • the obtained culture solution was centrifuged at 2330 X g for 15 minutes, and the supernatant was collected.
  • the supernatant was again centrifuged at 2330 Xg for 15 minutes and used as the culture supernatant.
  • the chimeric antibody was purified using MabTra ap kit (GE Healthcare) according to the manual. Using a peristaltic pump, almost the entire culture supernatant was applied to M ab T r a p (only 10 mL was collected for control). 10 ml_ of b i n d i n g b u f f er scrambled and eluted with 5 ml_ of e l u t i o n b u f f e r. At that time, 1 mL each was collected in 5 fractions. The elution fraction (N o. 2) with the highest protein concentration was dialyzed against PBS using S I id e -A-L i z e r (10 K) (P I E RC E).
  • the purified chimeric antibody was analyzed by Western plot. Electrophoresed on 4% polyacrylamide gel (Bio R ad), transferred to nylon membrane (M i II ipore), blocked with 5% skim milk, reacted with HRP-labeled anti-mouse IgG secondary antibody I let you. It was washed 3 times for 15 minutes each with ⁇ 3 containing 0.1% T ween 20 and a signal was obtained by chemiluminescence with EC L p lus (GE Healthcare). The signal was detected with LAS-1 000 (Fuji Photo Film). The results are shown in Figure 3. The purified chimeric antibody reacts with the anti-mouse IgG secondary antibody to produce a specific band.
  • the chimera antibody band has a higher mobility than that of the purified chimera antibody. This is because the amount of protein in the AI M_V medium that has a molecular weight close to that of the heavy chain is very large. it is conceivable that.
  • the amplified DNA fragment was treated with NotI and CIaI, separated by agarose electrophoresis, and purified by Qiaquick ⁇ IExtrtactiot ⁇ agen).
  • p L PCX and the chimeric antibody gene fragment were used for lysation with a ligation kit (Niibon Scene). The transformation was performed on the DH5 strain.
  • the plasmid thus prepared was pLP CX— FIT Cm I g G 2 a
  • FIG. 4 shows the result of confirming the expression of the chimeric antibody according to the technique of “5. Confirmation of expression and antigen recognition of the chimeric antibody”.
  • anti-FI TC chimeric antibody gene expression vector prepared by the technique described in “7_ 1. Insertion of anti-FI TC chimeric antibody gene into expression vector” above contains a restriction enzyme recognition sequence that is common to all tri-antibody sequences. It can be used for other specific antibody sequences with few operations.
  • p LPC XF IT Cm Ig G2a was treated with restriction enzymes NotI and PmaCI.
  • An antibody gene was obtained from the anti-EG FR antibody-producing strain by PCR in the same manner as in “3. Preparation of anti-FITC chicken I gM and mouse Ig G 2a chimeric antibody gene”.
  • VH—F 1—Not I — Xho I — B g III (SEQ ID NO: 9) and c Ig MCH 1 + h Ig G 1 hinge R (SEQ ID NO: 10) were used.
  • the obtained DNA fragment was treated with Not I and Pma CI.
  • Each DNA fragment was isolated by agarose electrolysis and purified by Qiaquick Gel Extraction kit (Qiagen).
  • Production of retrovirus and infection with D ⁇ 40 are carried out in the same manner as described in “7—2. Production of retrovirus and infection with D ⁇ 40” p L PCX—FIT Cm I g G 2 a instead of p L This was done using PCX_EG FR_I g G 2 a.
  • FIG. 5 shows the result of confirming the expression of the chimeric antibody according to the technique of “5. Confirmation of expression and antigen recognition of the chimeric antibody”.
  • the gene of the constant region of human Ig G 1 can be cloned from human RNA by a method common in the art.
  • P FUS E_h I g G 1 vector (Invivogen) has obtained the human Ig G 1 constant region gene from the p FUS E-h I g G 1 vector by PCR. Amplified.
  • hIgG1 + hinge15bp (SEQ ID NO: 1 1)
  • hIgG1-3—C Ia1 SEQ ID NO: 12
  • This DNA fragment was separated by agarose electrophoresis and purified by Q i aq u i ck G e l E xt r a c t i o n k i t. Let this DNA fragment be h i n g i G 1.
  • the gene for the anti-EG FR avian I gM and human I gG 1 chimeric antibody (hereinafter referred to as human trichimeric antibody) is the same as in “3-4.
  • p G EM— EGFR is a saddle type and the primer is VH— F 1— Not I _ X ho I _B g III (SEQ ID NO: 9) and c I g MCH 1 + h I g G 1
  • the combination of hinge R (SEQ ID NO: 10), and (ii) hinge G 1 DNA fragment prepared in 9_1 as a saddle type primer is G d I g M_C H 1 + h I g G 1 -F (SEQ ID NO: 1 3) and h I g G 1 -3_C I a 1 (SEQ ID NO: 1 2) were used.
  • the conditions were 98 ° C. for 2 minutes, 98 ° C. for 30 seconds, 58 ° C.
  • pAN TI—EG FR—hl gG I and p 1_ ⁇ ⁇ were treated with 1 ⁇ 10 0 1 and ⁇ 1 3 I, each DNA fragment was separated by agarose electrophoresis, and Q iaquick ⁇ e IE xtractionkit Made / Second. After that, Ligation was performed with pG EM_T (Promega) using Ligation kit (Nibonbon Gene). In this way, pLPCX—EGFR-hIgG1 was obtained.
  • Retrovirus production and infection with DT 40 are carried out in the same manner as described in “7—2. Retrovirus production and infection with DT 40” above.
  • P L PCX—FIT I g G 1 was used.
  • ELISA was performed as follows. Anti-avian IgM antibody (Bethy I) was dispensed at 50 g each into 96-well immunoplate U-96 Maxisorp (Nunc) at 10 g / ml and left to stand. Discard the contents of the plate the next day Put 200 L of blocking buffer (PBS containing 1% BSA) and incubate at room temperature for 1 hour. Washed 3 times with ELISA wash buffer (PBS containing 0.05% Tween 20) 200 1_. Thereafter, 100 L of each culture supernatant derived from the chimeric antibody-producing cells was added, and incubated at room temperature for 1 hour.
  • blocking buffer PBS containing 1% BSA
  • ELISA wash buffer PBS containing 0.05% Tween 20
  • the cell line A 43 1 derived from squamous cell carcinoma is known to express EGFR.
  • the mouse chimeric antibody treated with FITC-conjugated anti-mouse IgG antibody eBioscience
  • the human one-trichimeric antibody treated with FITC-conjugated anti-human Ig Staining was performed with G antibody (Southern Biotech). The stained cells were washed three times and then analyzed by FACSort (Beeton Dickin Son). The results are shown in Fig. 7.
  • the present invention can change the class of antibodies produced by antibody-producing cells to a desired class according to the application, the field of antibody preparations, antibody diagnostics, etc. Is widely available as a research tool.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé pour commuter une classe d'anticorps. De façon spécifique, l'invention concerne un moyen pour transformer un lymphocyte B donné capable de produire un anticorps monoclonal en un lymphocyte B capable de produire un anticorps ayant une classe commutée en une classe différente désirée par la préparation d'un gène d'anticorps à chaîne lourde chimérique, dans lequel un gène de région constante à chaîne lourde d'un anticorps monoclonal produit par le lymphocyte B produisant l'anticorps est substitué par un gène de région constante à chaîne lourde d'une classe différente désirée, et par la transformation du lymphocyte produisant l'anticorps initial par le gène chimérique. L'invention concerne également un anticorps ayant une classe commutée en une classe différente désirée, produit par le moyen.
PCT/JP2007/001029 2006-09-22 2007-09-21 Procédé de commutation de classe d'anticorps WO2008035463A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006256757A JP2009291073A (ja) 2006-09-22 2006-09-22 抗体のクラスを変換する方法
JP2006-256757 2006-09-22

Publications (1)

Publication Number Publication Date
WO2008035463A1 true WO2008035463A1 (fr) 2008-03-27

Family

ID=39200294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/001029 WO2008035463A1 (fr) 2006-09-22 2007-09-21 Procédé de commutation de classe d'anticorps

Country Status (2)

Country Link
JP (1) JP2009291073A (fr)
WO (1) WO2008035463A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011103876A (ja) * 2009-10-19 2011-06-02 Univ Of Tokyo キメラ抗体の一段階作製方法
US8679845B2 (en) 2007-05-31 2014-03-25 University Of Washington B cells modified to reversibly induce accelerated mutagenesis of target genes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011644A1 (fr) * 2002-07-30 2004-02-05 Riken Methode de promotion d'une recombinaison homologue de cellules somatiques et methode d'elaboration d'un anticorps specifique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011644A1 (fr) * 2002-07-30 2004-02-05 Riken Methode de promotion d'une recombinaison homologue de cellules somatiques et methode d'elaboration d'un anticorps specifique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OWENS R.J. ET AL.: "The genetic engineering of monoclonal antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 168, no. 2, 1994, pages 149 - 165, XP002914829 *
SEO H. ET AL.: "Rapid generation of specific antibodies by enhanced homologous recombination", NATURE BIOTECHNOLOGY, vol. 23, no. 6, 2005, pages 731 - 735, XP002377926 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679845B2 (en) 2007-05-31 2014-03-25 University Of Washington B cells modified to reversibly induce accelerated mutagenesis of target genes
US9273119B2 (en) 2007-05-31 2016-03-01 University Of Washington Inducible mutagenesis of target genes
US9815885B2 (en) 2007-05-31 2017-11-14 University Of Washington Inducible mutagenesis of target genes
JP2011103876A (ja) * 2009-10-19 2011-06-02 Univ Of Tokyo キメラ抗体の一段階作製方法

Also Published As

Publication number Publication date
JP2009291073A (ja) 2009-12-17

Similar Documents

Publication Publication Date Title
EP3037525B1 (fr) Procédé de production d'une molécule de liaison à l'antigène dans lequel on utilise un phage auxiliaire modifié
TWI359028B (en) Bivalent, bispecific antibodies
JP3444885B2 (ja) Ｌ鎖欠落免疫グロブリン
JP7001474B2 (ja) 非免疫原性単一ドメイン抗体
KR102180660B1 (ko) 발현 방법
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
CN111518214A (zh) 靶向cldn18.2的双特异性抗体及其制备方法和应用
AU2016309738A1 (en) Antibody or antibody fragment or non-Ig scaffold binding to a binding region of an anti-NMDARI-D-aspartate (NMDA) receptor antibody
AU2022287551A1 (en) Mixed binding domains
WO2008035463A1 (fr) Procédé de commutation de classe d'anticorps
CN110642947B (zh) 抗人cd147的单克隆抗体、表达载体、细胞株及其应用
US9850317B2 (en) Anti-dog IgE monoclonal antibody, and light-chain variable region and heavy-chain variable region of anti-dog IgE monoclonal antibody
JP2004533264A (ja) バクテリオファージのシグナルペプチドをコードする発現ベクター
US20230235039A1 (en) Il-5 binding molecule, preparation method therefor, and use thereof
KR20240130125A (ko) 항-gprc5d 항체 및 그의 응용
CN118063606B (zh) 一种抗thsd7a单克隆抗体及其制备方法和应用
CN117384290B (zh) 人源robo1结合分子及其应用
JP7446342B2 (ja) 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
CN112279913B (zh) 一种抗人il-6单克隆抗体及应用
WO2010097435A1 (fr) Procédé de production d'anticorps
KR20190075071A (ko) 프래그먼트 항체 및 당해 프래그먼트 항체를 이용하는 단백질의 결정화 방법
WO2024229245A2 (fr) Génération et classement de fragments d'anticorps fab à haut débit
CN118725102A (zh) cTnI抗体及其用途
CN112079928A (zh) 一种抗pd-l1的单克隆抗体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827808

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07827808

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP